Building on these findings, we engineered a recombinant oncolytic vaccinia virus (OVV-NbTIM3) expressing single-domain antibodies targeting murine/human TIM-3, which effectively reprograms immunosuppressive TME landscapes toward pro-inflammatory phenotypes conducive to tumor clearance. Here, HAVCR2 is linked to neoplasm.